Preserving functional SDF-1 by DPPIV inhibition after ischemia may enhance stem cell therapies by targeting CD34(+)CXCR4(+) cells to the ischemic heart and attenuating ischemic cardiomyopathy.
Does targeting the SDF-1-CXCR4 axis improve stem cell homing and attenuate ischemic cardiomyopathy?
Preserving functional SDF-1 via DPPIV inhibition may enhance stem cell homing and improve therapies for ischemic cardiomyopathy.
IMPORTANCE OF THE FIELD: Ischemic disorders are the leading cause of mortality worldwide, current therapies only delay progression of the disease. Data suggest a role of the SDF-1-CXCR4 axis in attenuation of ischemic disorders. AREAS COVERED IN THIS REVIEW: We discuss the importance of SDF-1-CXCR4 interactions during development and postnatal mobilization and migration of stem cells. We focus on the role of the SDF-1-CXCR4 axis in stem-cell-based applications for attenuation of ischemic cardiomyopathy. WHAT THE READER WILL GAIN: During development the SDF-1-CXCR4 axis plays a critical role in gradient-guided cell movements. In adults, the SDF-1-CXCR4 axis is involved in retention and mobilization of stem cells. Since SDF-1 is upregulated during hypoxic tissue damage, strategies to augment or stabilize SDF-1 have been utilized to target blood-derived stem cells to ischemic tissue. We exploited this concept by preventing SDF-1 degradation with dipeptidylpeptidaseIV (DPPIV) inhibition and mobilization of stem cells by G-CSF after acute myocardial infarction. This targeted CD34(+)CXCR4(+) cells to ischemic heart and attenuated ischemic cardiomyopathy. TAKE HOME MESSAGE: The SDF-1-CXCR4 axis plays a role in stem cell homing during embryogenesis and adulthood especially after ischemia. Preserving functional SDF-1 by DPPIV inhibition after ischemia may enhance stem cell therapies.
Zaruba et al. (Thu,) conducted a review in Ischemic cardiomyopathy. DPPIV inhibition and G-CSF was evaluated. Preserving functional SDF-1 by DPPIV inhibition after ischemia may enhance stem cell therapies by targeting CD34(+)CXCR4(+) cells to the ischemic heart and attenuating ischemic cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: